Cargando…

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer

Detalles Bibliográficos
Autores principales:	Sadoff, Jerald, Davis, Kourtney, Douoguih, Macaya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117965/ https://www.ncbi.nlm.nih.gov/pubmed/33861522 http://dx.doi.org/10.1056/NEJMc2106075

Ejemplares similares

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination
por: Muir, Kate-Lynn, et al.
Publicado: (2021)

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
por: Barouch, Dan H., et al.
Publicado: (2021)

Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )
por: Le Gars, Mathieu, et al.
Publicado: (2022)

Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19
por: Barouch, Dan H., et al.
Publicado: (2021)

Ad26.COV2-S: Thrombotic thrombocytopenia: case report
Publicado: (2021)

Ad26.cov2-s: Thrombotic thrombocytopenia: case report
Publicado: (2022)

Ad26.COV2-S: Thrombotic thrombocytopenia: case report
Publicado: (2021)

Ad26.COV2-S: Immune thrombotic thrombocytopenia: case report
Publicado: (2022)

Ad26.cov2-s: Immune thrombotic thrombocytopenia: case report
Publicado: (2022)

Ad26.cov2-s: Immune-thrombotic thrombocytopenia: case report
Publicado: (2022)

Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials
por: Sadoff, Jerald, et al.
Publicado: (2022)

PF4 Immunoassays in Vaccine-Induced Thrombotic Thrombocytopenia
por: Vayne, Caroline, et al.
Publicado: (2021)

Ad26.COV2-S/AZD-1222: Thrombotic thrombocytopenia: 5 case reports
Publicado: (2022)

Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination
por: Yocum, Andrew, et al.
Publicado: (2021)

Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination
por: Clark, Richard Todd, et al.
Publicado: (2021)

Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia
por: Patriquin, Christopher J., et al.
Publicado: (2021)

LB7. Ad26.COV2.S-Elicted Neutralizing Activities Against SARS-CoV-2 Variants of Concern in Phase 1/2a and Phase 3 Clinical Trials
por: Le Gars, Mathieu, et al.
Publicado: (2021)

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
por: Greinacher, Andreas, et al.
Publicado: (2021)

Ad26.COV2-S: Thrombotic thrombocytopenia and cerebral venous sinus thrombosis: case report
Publicado: (2021)

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
por: Alter, Galit, et al.
Publicado: (2021)

Lymphohistocytic myocarditis after Ad26.COV2.S viral vector COVID-19 vaccination
por: Ujueta, Francisco, et al.
Publicado: (2021)

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
por: Sadoff, Jerald, et al.
Publicado: (2021)

Persistence of Ad26.COV2.S‐associated vaccine‐induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies
por: Kanack, Adam J., et al.
Publicado: (2022)

Kidney Transplantation from a Deceased Donor with COVID-19 Ad26.COV2-S Vaccine-Induced Thrombotic Thrombocytopenia
por: Neretljak, Ivan, et al.
Publicado: (2023)

Comment on “Vaccine induced thrombotic thrombocytopenia: The shady chapter of a success story”
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study
por: Takuva, Simbarashe, et al.
Publicado: (2021)

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
por: Hardt, Karin, et al.
Publicado: (2022)

Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Alexandre, Marie, et al.
Publicado: (2023)

Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COV2.S vaccination
por: Kulkarni, Prathit A., et al.
Publicado: (2021)

Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COV2.S: first documented case outside US
por: Rodriguez, Elsa V. C., et al.
Publicado: (2021)

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
por: Sadoff, Jerald, et al.
Publicado: (2022)

Antibody Response to the Coronavirus Disease 2019 Ad26.COV2.S Vaccine Among Maintenance Dialysis Patients
por: Ficociello, Linda H., et al.
Publicado: (2022)

2321. Long-term immunogenicity of Ad26.RSV.preF/RSV preF protein vaccine against RSV in a phase 2b study by age and risk level
por: Comeaux, Christy A, et al.
Publicado: (2022)

Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID‐19 vaccine Ad26.COV2.S in humans
por: Dari, Anna, et al.
Publicado: (2023)

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
por: Sadoff, Jerald, et al.
Publicado: (2021)

COVID‐19 mRNA‐1273 vaccine induces production of vaccine‐induced immune thrombotic thrombocytopenia antibodies
por: Padmanabhan, Anand, et al.
Publicado: (2022)

Ad26.cov2-s/AZD-1222: Cerebral venous sinus thrombosis and thrombotic thrombocytopenia: 3 case reports
Publicado: (2022)

Thrombus Distribution in Vaccine-induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
por: Rogers, Priya, et al.
Publicado: (2022)

Ad26.COV2-S: Thrombocythemia-thrombotic: case report
Publicado: (2022)

Letter to editor – observation on the article titled “Vaccine-Induced Thrombotic Thrombocytopenia (VITT): first report from India”
por: Kotwal, Jyoti, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t3l665vp1ir57c7mejmn516enp